Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056 is registered in ClinicalTrials.gov with Arcutis Biotherapeutics, Inc. as lead sponsor.

NCT NCT06998056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06998056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Lead sponsor
Arcutis Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2025
Completion date
December 4, 2025
Enrollment
101 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (eczema)